Business Wire

Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19

WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336 ...
Nasdaq

Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of ...

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, ...